Leukemia, Myelocytic, Acute Clinical Trial
Official title:
Phase II Study of Cladribine, High-dose Cytarabine and Idarubicin in Patients With Relapsed Acute Myeloid Leukemia
The purpose of this study is to evaluate the safety and the efficacy of cladribine, high-dose cytarabine and idarubicin in the treatment of patients with relapsed acute myeloid leukemia.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | March 2011 |
Est. primary completion date | November 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients with relapsed AML with a remission duration of at least 6 months after first complete remission (CR) or of at least 3 months after second (or higher) CR - Age >= 18 years - Life expectancy of at least three months (without consideration of AML and complications) - Eastern Cooperative Oncology Group (ECOG) 0-2 (without consideration of AML and complications) - Written informed consent Exclusion Criteria: - Prior therapy of AML with cladribine - Severe, uncontrolled infection at time of inclusion (enrollment is possible after control of infection) - Cardiac insufficiency grade III or IV New York Heart Association (NYHA) - Severe renal insufficiency with a clearance of < 30 ml/min (if not due to AML) - Severe hepatic insufficiency with bilirubin > 3 mg/dl or AST > 200 U/l (if not due to AML) - Other severe organ impairment grade III or IV World Health Organization (WHO) (if not due to AML or, in the opinion of the investigator, may not interfere with the procedures in the study) - HIV infection - Intolerance to study drugs - Pregnant or breast-feeding women - Any other malignant disease which will probably affect the course of AML |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | Medical Clinic & Policlinic III, University Bonn | Bonn |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Bonn |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Toxicity according to National Cancer Institute/Common Toxicity Criteria (NCI/CTC), especially the rate of severe infections and the death rate | continuous | Yes | |
Primary | Rate of complete remission | No | ||
Secondary | Remission duration | No | ||
Secondary | Overall survival | No | ||
Secondary | Influence of cytogenetic aberrations on remission rate, duration of remission and overall survival | No | ||
Secondary | Course of CD3/CD4+ subpopulation after therapy | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00393380 -
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
|
Phase 2 | |
Completed |
NCT01716793 -
Risk-adapted Therapy for Adult Acute Myeloid Leukemia.
|
Phase 2 | |
Terminated |
NCT00152594 -
Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia
|
Phase 3 | |
Completed |
NCT01723657 -
Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT01034592 -
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
|
N/A | |
Completed |
NCT00406393 -
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
|
Phase 3 | |
Recruiting |
NCT00449319 -
AML Treatment in Untreated Adult Patients
|
N/A | |
Completed |
NCT00186381 -
Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission
|
Phase 2 | |
Completed |
NCT00962767 -
Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission
|
Phase 3 | |
Completed |
NCT01756118 -
A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
|
Phase 1 | |
Terminated |
NCT01339910 -
Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)
|
Phase 3 | |
Completed |
NCT00201240 -
Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303)
|
Phase 2 | |
Terminated |
NCT01050946 -
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit
|
Phase 2 | |
Terminated |
NCT00446303 -
A Phase II Study of Maintenance With Azacitidine in MDS Patients
|
Phase 2 | |
Completed |
NCT00044486 -
Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)
|
Phase 3 | |
Active, not recruiting |
NCT02158858 -
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
|
Phase 1/Phase 2 | |
Completed |
NCT00286845 -
Use of the MiCK Assay for Apoptosis in AML
|
Phase 1 | |
Completed |
NCT00251368 -
Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia
|
Phase 1 | |
Terminated |
NCT00048100 -
Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes
|
Phase 1 | |
Recruiting |
NCT02895412 -
Infection and Tumour Antigen Cellular Therapy
|
Phase 1 |